Skip to main content

Market Overview

Suspensions In Europe Will Not Disturb AstraZeneca Vaccine's Global Roll Out: Report

Share:

The World Health Organization said that global distribution of the AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine remains unruffled, though much of Europe has stopped using the shot after reports of blood clots in some people shortly after immunization, reports Washington Post.

  • The EMA has not recommended that authorities suspend the use and WHO also came out to advise against halting vaccinations.
  • Sweden and Latvia are the latest European countries to pause the vaccinations against COVID-19 using AstraZeneca’s vaccine as a precautionary measure.
  • The reassurance from WHO comes as Australia said that it would continue to use the vaccine, which successfully protects against the infection. 
  • Thailand’s prime minister also became the country’s first person to be vaccinated with the AstraZeneca shot after the country briefly halted its rollout due to blood clot concerns in Europe.
  • Bloomberg notes that Africa Centers for Disease Control is reviewing the shot amid the possible safety concerns.
  • Price Action: AZN shares are trading 2.58% higher at $50.03 in premarket on the last check Tuesday.
 

Related Articles (AZN + AZNCF)

View Comments and Join the Discussion!

Posted-In: COVID-19 Vaccine The Washington Post World Health OrganizationBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com